REED JOHN C
Insider CIK 1181561 · MDGL Director · CLVS Director · JNJ EVP, Pharmaceuticals R&D · ISIS Director
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| MDGL MADRIGAL PHARMACEUTICALS, | A Award deriv | 2026-08-15 | 2026-08-18 | 1,078 | — | $0 | 1,078 | SEC↗ |
| MDGL MADRIGAL PHARMACEUTICALS, | A Award | 2026-08-15 | 2026-08-18 | 647 | — | $0 | 647 | SEC↗ |
| MDGL MADRIGAL PHARMACEUTICALS, | A Award deriv | 2026-08-15 | 2026-08-18 | 1,078 | — | $0 | 1,078 | SEC↗ |
| MDGL MADRIGAL PHARMACEUTICALS, | A Award | 2026-08-15 | 2026-08-18 | 647 | — | $0 | 647 | SEC↗ |
| JNJ JOHNSON & JOHNSON | M Exercise deriv | 2026-05-01 | 2026-05-04 | 25,255 | — | $0 | 0 | SEC↗ |
| JNJ JOHNSON & JOHNSON | M Exercise | 2026-05-01 | 2026-05-04 | 25,255 | — | $0 | 35,913 | SEC↗ |
| JNJ JOHNSON & JOHNSON | F Tax w/h | 2026-05-01 | 2026-05-04 | 11,002 | $229.85 | $2.53M | 24,911 | SEC↗ |
| JNJ JOHNSON & JOHNSON | M Exercise deriv | 2026-02-17 | 2026-02-18 | 29,927 | — | $0 | 59,854 | SEC↗ |
| JNJ JOHNSON & JOHNSON | M Exercise deriv | 2026-02-17 | 2026-02-18 | 21,721 | — | $0 | 21,721 | SEC↗ |
| JNJ JOHNSON & JOHNSON | M Exercise | 2026-02-17 | 2026-02-18 | 21,721 | $157.92 | $3.43M | 34,662 | SEC↗ |
| JNJ JOHNSON & JOHNSON | S Sale | 2026-02-17 | 2026-02-18 | 21,721 | $243.00 | $5.28M | 12,941 | SEC↗ |
| JNJ JOHNSON & JOHNSON | S Sale | 2026-02-17 | 2026-02-18 | 2,283 | $243.00 | $554.8K | 10,658 | SEC↗ |
| JNJ JOHNSON & JOHNSON | S Sale | 2026-02-17 | 2026-02-18 | 29,927 | $243.00 | $7.27M | 12,941 | SEC↗ |
| JNJ JOHNSON & JOHNSON | M Exercise | 2026-02-17 | 2026-02-18 | 29,927 | $156.15 | $4.67M | 42,868 | SEC↗ |
| JNJ JOHNSON & JOHNSON | M Exercise deriv | 2026-02-15 | 2026-02-18 | 1,349 | — | $0 | 1,349 | SEC↗ |
| JNJ JOHNSON & JOHNSON | M Exercise deriv | 2026-02-15 | 2026-02-18 | 1,847 | — | $0 | 3,692 | SEC↗ |
| JNJ JOHNSON & JOHNSON | A Award deriv | 2026-02-15 | 2026-02-18 | 49,382 | — | $0 | 49,382 | SEC↗ |
| JNJ JOHNSON & JOHNSON | A Award deriv | 2026-02-15 | 2026-02-18 | 3,546 | — | $0 | 3,546 | SEC↗ |
| JNJ JOHNSON & JOHNSON | F Tax w/h | 2026-02-15 | 2026-02-18 | 385 | $243.45 | $93.7K | 11,622 | SEC↗ |
| JNJ JOHNSON & JOHNSON | F Tax w/h | 2026-02-15 | 2026-02-18 | 528 | $243.45 | $128.5K | 12,941 | SEC↗ |
| JNJ JOHNSON & JOHNSON | M Exercise | 2026-02-15 | 2026-02-18 | 1,847 | — | $0 | 13,469 | SEC↗ |
| JNJ JOHNSON & JOHNSON | M Exercise | 2026-02-15 | 2026-02-18 | 1,349 | — | $0 | 12,007 | SEC↗ |
| JNJ JOHNSON & JOHNSON | M Exercise deriv | 2025-10-17 | 2025-10-20 | 21,721 | $157.92 | $3.43M | 43,442 | SEC↗ |
| JNJ JOHNSON & JOHNSON | S Sale | 2025-10-17 | 2025-10-20 | 21,721 | $192.71 | $4.19M | 10,658 | SEC↗ |
| JNJ JOHNSON & JOHNSON | M Exercise | 2025-10-17 | 2025-10-20 | 21,721 | $157.92 | $3.43M | 32,379 | SEC↗ |
| JNJ JOHNSON & JOHNSON | S Sale | 2025-07-17 | 2025-07-18 | 19,137 | $163.55 | $3.13M | 10,658 | SEC↗ |
| JNJ JOHNSON & JOHNSON | M Exercise deriv | 2025-05-01 | 2025-05-05 | 25,255 | — | $0 | 25,255 | SEC↗ |
| JNJ JOHNSON & JOHNSON | F Tax w/h | 2025-05-01 | 2025-05-05 | 11,002 | $156.31 | $1.72M | 29,795 | SEC↗ |
| JNJ JOHNSON & JOHNSON | M Exercise | 2025-05-01 | 2025-05-05 | 25,255 | — | $0 | 40,797 | SEC↗ |
| JNJ JOHNSON & JOHNSON | F Tax w/h | 2025-02-18 | 2025-02-18 | 385 | $156.15 | $60.1K | 15,542 | SEC↗ |
| JNJ JOHNSON & JOHNSON | M Exercise deriv | 2025-02-15 | 2025-02-18 | 1,350 | — | $0 | 2,698 | SEC↗ |
| JNJ JOHNSON & JOHNSON | A Award deriv | 2025-02-15 | 2025-02-19 | 89,781 | — | $0 | 89,781 | SEC↗ |
| JNJ JOHNSON & JOHNSON | A Award deriv | 2025-02-15 | 2025-02-19 | 5,539 | — | $0 | 5,539 | SEC↗ |
| JNJ JOHNSON & JOHNSON | M Exercise | 2025-02-15 | 2025-02-18 | 1,350 | — | $0 | 15,927 | SEC↗ |
| JNJ JOHNSON & JOHNSON | M Exercise deriv | 2024-05-01 | 2024-10-31 | 25,255 | — | $0 | 50,510 | SEC↗ |
| JNJ JOHNSON & JOHNSON | F Tax w/h | 2024-05-01 | 2024-10-31 | 10,984 | $144.59 | $1.59M | 14,577 | SEC↗ |
| JNJ JOHNSON & JOHNSON | M Exercise | 2024-05-01 | 2024-10-31 | 25,255 | — | $0 | 25,561 | SEC↗ |
| JNJ JOHNSON & JOHNSON | M Exercise deriv | 2024-05-01 | 2024-05-03 | 22,255 | — | $0 | 53,510 | SEC↗ |
| JNJ JOHNSON & JOHNSON | F Tax w/h | 2024-05-01 | 2024-05-03 | 10,984 | $144.59 | $1.59M | 11,577 | SEC↗ |
| JNJ JOHNSON & JOHNSON | M Exercise | 2024-05-01 | 2024-05-03 | 22,255 | — | $0 | 22,561 | SEC↗ |
| JNJ JOHNSON & JOHNSON | A Award deriv | 2024-02-15 | 2024-02-20 | 4,048 | — | $0 | 4,048 | SEC↗ |
| JNJ JOHNSON & JOHNSON | A Award deriv | 2024-02-15 | 2024-02-20 | 65,163 | — | $0 | 65,163 | SEC↗ |
| JNJ JOHNSON & JOHNSON | A Award deriv | 2023-05-01 | 2023-05-02 | 75,765 | — | $0 | 75,765 | SEC↗ |
| ISIS ISIS PHARMACEUTICALS INC | M Exercise deriv | 2012-09-06 | 2012-09-06 | 4,900 | — | $0 | 0 | SEC↗ |
| ISIS ISIS PHARMACEUTICALS INC | M Exercise | 2012-09-06 | 2012-09-06 | 4,900 | $5.17 | $25.3K | 4,900 | SEC↗ |
| ISIS ISIS PHARMACEUTICALS INC | S Sale | 2012-09-06 | 2012-09-06 | 4,900 | $15.18 | $74.4K | 0 | SEC↗ |
| ISIS ISIS PHARMACEUTICALS INC | M Exercise deriv | 2012-09-04 | 2012-09-06 | 5,100 | — | $0 | 4,900 | SEC↗ |
| ISIS ISIS PHARMACEUTICALS INC | S Sale | 2012-09-04 | 2012-09-06 | 5,100 | $15.17 | $77.4K | 0 | SEC↗ |
| ISIS ISIS PHARMACEUTICALS INC | M Exercise | 2012-09-04 | 2012-09-06 | 5,100 | $5.17 | $26.4K | 5,100 | SEC↗ |
| ISIS ISIS PHARMACEUTICALS INC | M Exercise deriv | 2012-07-09 | 2012-07-11 | 10,000 | — | $0 | 0 | SEC↗ |
| ISIS ISIS PHARMACEUTICALS INC | M Exercise | 2012-07-09 | 2012-07-11 | 10,000 | $3.95 | $39.5K | 10,000 | SEC↗ |
| ISIS ISIS PHARMACEUTICALS INC | S Sale | 2012-07-09 | 2012-07-11 | 10,000 | $13.99 | $139.9K | 0 | SEC↗ |
| ISIS ISIS PHARMACEUTICALS INC | A Award deriv | 2012-07-02 | 2012-07-03 | 1,250 | — | $0 | 1,250 | SEC↗ |
| ISIS ISIS PHARMACEUTICALS INC | A Award deriv | 2012-07-02 | 2012-07-03 | 11,250 | — | $0 | 11,250 | SEC↗ |
| ISIS ISIS PHARMACEUTICALS INC | M Exercise deriv | 2012-06-22 | 2012-06-22 | 10,000 | — | $0 | 0 | SEC↗ |
| ISIS ISIS PHARMACEUTICALS INC | M Exercise | 2012-06-22 | 2012-06-22 | 10,000 | $8.15 | $81.5K | 10,000 | SEC↗ |
| ISIS ISIS PHARMACEUTICALS INC | S Sale | 2012-06-22 | 2012-06-22 | 10,000 | $11.06 | $110.6K | 0 | SEC↗ |
| CLVS Clovis Oncology, Inc. | A Award deriv | 2012-06-14 | 2012-06-15 | 12,414 | — | $0 | 12,414 | SEC↗ |